Skip to main
STIM

Neuronetics Inc (STIM) Stock Forecast & Price Target

Neuronetics Inc (STIM) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neuronetics is positioned favorably because the December 2024 acquisition of Greenbrook TMS converted it into a vertically integrated interventional psychiatry platform with 93 company-operated treatment centers, creating scale in a fragmented market and immediate leverage from fixed clinic costs. Its Q2 results showed total revenue of $41.6M, Greenbrook revenue up 17% y/y to $26.9M, gross margin expansion to 51.1%, and first-time positive adjusted EBITDA of $0.3M, all supported by better reimbursement, cleaner claims, and tighter collections. On the NeuroStar side, the shift to a three-pathway commercial model and the AdvancedMD integration should broaden the addressable customer base, while the company’s collaboration with Compass Pathways and SPRAVATO infrastructure could make it an early beneficiary of next-generation therapies in 2027.

Bears say

Neuronetics is pressured by inconsistent commercial execution, the risk of slower procedure volumes, and intensifying competition and pricing pressure in a market that still depends on adoption of its NeuroStar TMS platform. Although it ended Q2 with $25.0M in total cash after $7.6M of ATM proceeds, that liquidity improvement came alongside continued cash usage and a full-year cash flow from operations and investing guide of -$10.5M to -$14.5M, underscoring ongoing funding needs. Its outlook is further weakened by regulatory delays, limited uptake of new products, and higher-than-expected operating expenses, all of which could constrain sales leverage and margin improvement.

Neuronetics Inc (STIM) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neuronetics Inc (STIM) Forecast

Analysts have given Neuronetics Inc (STIM) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Neuronetics Inc (STIM) has a Strong Buy consensus rating as of Oct 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neuronetics Inc (STIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.